View Pages
Vertex to Buy Crinetics for $10B; Solstice to Acquire Element; TeraWulf Rally
Vertex agrees to buy Crinetics for $10B; Solstice acquires Element in a $14.5B cash-and-stock deal; TeraWulf jumps after Anthropic lease and asset sale — top stock movers today.
Editorial companion
What stands out
Vertex agreed to buy Crinetics for $10 billion, paying $85 a share, a 102% premium, to bulk up its endocrinology pipeline, including treatments for acromegaly, in a deal expected to close in the third quarter. That transaction converts a binary clinical-development story into an acquisition story overnight, shifting the calculus for anyone valuing Vertex as a growth-through-innovation company. For investors, the move narrows one kind of uncertainty, late-stage trial risk, while creating another: did Vertex pay too much for speed and scale?
Bullish Gator Snapshot
Current ratings and signals
Vertex Pharmaceuticals (VRTX)
Bullish
VRTX rates Bullish overall. The fundamental read is bullish: the company passes 5 of 9 quality tests on the Piotroski F-Score; balance sheet is in the Safe zone (Altman Z = 13.51); revenue is growing about 10.4% per year; net income is growing about 9.0% per year. The technical picture is bullish: price is 8.4% above the 200-day moving average; 1.0% below the 50-day; the 50/200 relationship is in a Golden cross. Sentiment is bullish (composite 80/100), based on 8 news articles from recent coverage.